The development of efficient and safe methods for in vivo gene transfer is central to the success of gene therapy. Recombinant adenoviral vectors, although highly efficient, are limited by the host immune response, potential safety hazards due to obligatory cotransfer of viral proteins, and their broad tissue tropism. Here, we demonstrate in an animal model that host range and tissue tropism of a recombinant adenovirus from a distant species can be modified by complexing adenovirus with a cell-specific ligand. Thus, a
Introduction
Adenoviral vectors have recently emerged as attractive gene delivery systems. 1 With increasing experience with recombinant adenoviral vectors, however, two major problems became evident. First, the broad cell tropism limits the tissue specificity of gene expression. Successful retargeting of adenovirus vectors has been reported in vitro in several studies by the construction of variant fiber proteins [2] [3] [4] [5] [6] or using a bispecific antibody approach. [7] [8] [9] [10] [11] Previously reported in vitro data addressed the possibility of targeting recombinant adenoviruses to the transferrin receptors of K562 cells constructing molecular conjugate vectors 12 and to the c-Kit receptor by addition of the biotinylated ligand. 13 Second, previously or newly acquired adenoviral infections might affect the efficiency and safety of recombinant adenoviral vectors in several ways. As an alternative to human adenoviruses, adenoviruses from distant species are currently being explored. This approach might have several advantages: toxicity should be significantly lower due to a lack of adenoviral replication or gene expression; safety should be higher because pre-existing or acquired infection with wild-type adenovirus should not trans-complement the therapeutic vector.
14 Further, adenoviruses from distant species would be less hazardous to the investigator and would be less affected by pre-existing antibodies against human or murine adenoviruses. 15 In an initial study Cotten et al 16 have shown that a recombinant avian adenovirus (CELO) replication-deficient lacZ recombinant human adenovirus, which naturally does not infect avian cells, allowed highly efficient and specific gene transfer to the liver of ducks in vivo when complexed with N-acetylglucosamine, a ligand for the chicken hepatic lectin. This combination of ligandmediated receptor targeting with adenoviral uptake and intracellular processing of a given gene represents a novel approach to gene therapy of inherited and acquired liver diseases. Gene Therapy (2000) 7, 1039-1045.
can indeed be used to efficiently transduce mammalian cells in vitro. However, no data are available to date demonstrating the efficiency of this system for in vivo gene transfer.
Here we describe a new approach to adenoviral gene transfer technology that aims at retargeting an adenovirus of a distant species to selected tissue in a new host by complexing it with a well characterized, natural ligand. An avian animal model was chosen to study gene transfer to the liver. The chicken hepatic lectin (CHL) was selected for ligand-mediated receptor targeting. This lectin is involved in the clearance of N-acetylglucosamineterminated serum glycoproteins. Whereas the asialoglycoprotein-receptor (ASGP-R) has been detected in all mammalian livers examined to date, avian livers are devoid of such lectins but contain receptors that bind Nacetylglucosamine-terminated glycoproteins.
17,18 Among calcium-dependent animal lectins, the CHL is unique in displaying almost complete selectivity for N-acetylglucosamine over other monosaccharide ligands. 19 The structure of the gene encoding CHL established this receptor as the evolutionary homolog of the mammalian ASGP-R. 20 It is interesting that the chicken receptor falls into a subfamily of proteins along with the mammalian ASGP-R, since the saccharide-binding specificity of the CHL resembles more closely that of a different set of calciumdependent animal lectins, which includes the mannosebinding proteins. In mammals there is no evidence that N-acetylglucosamine-terminated proteins bind to the ASGP-R. However, the existence of a mannose/N-acetylglucosamine binding protein has been described. 21 Several studies have previously shown that the ASGP-R, which is unique to liver cells, can be used to direct drugs and genetic material to hepatocytes. Thus, plasmid DNA and oligodeoxynucleotides can be targeted to hepatocytes in vitro when complexed to ASGP. [22] [23] [24] [25] [26] [27] By adding adenoviral particles to the complex DNA uptake via the endosomal pathway is significantly enhanced. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Taking this concept one step further we now report that replicationdefective human adenovirus highly efficiently transduces avian hepatocytes in vivo when complexed to N-acetylglucosamine-modified bovine serum albumin (BSA). We describe that in vitro and in vivo transduction rates are greatly enhanced when the reporter gene is delivered as an integral part of recombinant adenovirus rather than as a separate plasmid component of the complex.
Results
Efficiency and specificity of the adenoviral, receptormediated DNA delivery complex in vitro The adenoviral, receptor-mediated DNA delivery complex (AdlacZ-Lig/pL) consisted of AdlacZ, protein conjugate and carrier DNA (Figure 1 ). The protein conjugate consisted of N-acetylglucosamine-modified BSA (Lig), streptavidin and poly-l-lysine (pL). Reporter assays were performed 24 h after infection/transfection with the complexes described above. Table 1 compares the gene delivery efficiency after infection with AdlacZ and after transfection with AdlacZ-Lig/pL, respectively, in three different cell types: the chicken hepatoma cell line LMH, primary duck hepatocytes and the human hepatoma cells HepG2. The amount of adenovirus in each experiment was 1 × 10 7 pfu. In infection experiments 1 × 10 7 pfu AdlacZ were incubated with 500 000 cells. In transfection experiments 1 × 10 7 pfu AdlacZ were incorporated into AdlacZ-Lig/pL complexes. AdlacZ showed low infec- To study the uptake route of AdlacZ and AdlacZLig/pL into primary hepatocytes, free specific ligand or a non-relevant control protein were added in 10-, 20-, 50-and 200-fold excess. Addition of free ligand to AdlacZLig/pL reduced transduction efficiency in a dose-dependent manner to a level comparable to that of AdlacZ alone, competition assays using the free ligand N-acetylglucosamine BSA and the control protein BSA in 200-fold excess are shown in Figure 2 . No significant inhibition was observed after addition of the control protein BSA to AdlacZ-Lig/pL. In primary duck hepatocytes, no significant change in the low transduction of AdlacZ was observed after addition of free specific ligand or control protein. From these competition experiments it can be concluded that in primary hepatocytes the main uptake route of AdlacZ-Lig/pL is via the CHL. Small amounts of the complexes may enter via adenoviral receptors which are not blocked by the specific ligand and possibly correspond to the low-level transduction seen with uncomplexed AdlacZ.
Efficiency and specificity of the adenoviral, receptormediated DNA delivery complex in vivo As described above the adenoviral, receptor-mediated DNA delivery complex (AdlacZ-Lig/pL) consisted of AdlacZ, protein conjugate and carrier DNA ( Figure 1 ). AdlacZ-Lig/pL complexes containing 1 × 10 9 pfu adenoviral particles and AdlacZ-ASOR/pL complexes containing 1 × 10 9 pfu adenoviral particles and the control ligand asialoorosomucoid (ASOR) were constructed. These complexes, AdlacZ alone (1 × 10 9 pfu) or buffer were injected into the foot vein of 5-day-old ducklings (four animals each). Two days later the ducklings were killed and ␤-galactosidase (␤-gal) expression in the liver was analyzed by 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal) staining (Figure 3) . Compared with the control ducks and ducks infected with AdlacZ alone, a highly efficient gene transfer could be seen in the livers of the ducks injected with AdlacZ-Lig/pL. Only very low level gene delivery could be seen in the livers of ducks injected with AdlacZ-ASOR/pL complexes comparable to infection with AdlacZ alone. Because ASOR does not bind to the CHL due to the almost complete selectivity of CHL for N-acetylglucosamine-terminated glycoproteins these data demonstrate the specific and efficient uptake of AdlacZ-Lig/pL via the CHL.
To quantitate and to identify the targeted cell type in the liver, AdGFP-Lig/pL complexes were constructed containing 1 × 10 9 pfu adenoviral particles. These complexes, AdGFP alone (1 × 10 9 pfu) or buffer were injected into the foot vein of ducklings. Two days later the ducklings were killed, a single-cell suspension of liver cells was prepared by collagenase digestion and green fluorescent protein (GFP) expressing liver cells were identified by fluorescence microscopy or flow cytometry. As shown in Figure 4 , liver cells from control ducks and ducks treated with AdGFP alone showed only minimal GFP expression. By contrast, a high percentage of liver cells isolated from ducks treated with AdGFP-Lig/pL expressed GFP. Quantitation by flow cytometry ( Figure  5 ) demonstrated that about 2% of liver cells isolated from ducks treated with AdGFP alone expressed GFP. By contrast, about 50% of liver cells isolated from ducks treated with AdGFP-Lig/pL showed GFP expression.
Further, it could be shown that the presence of carrier DNA is necessary for an efficient gene transfer. In the in vitro and in vivo experiments described above carrier DNA was an integral component of the delivery complex. In control experiments using complexes without carrier DNA gene transfer efficiency was comparable to that of AdlacZ alone. In order to study a possible gene expression of plasmid carrier DNA we used the luciferase a b c d Gene Therapy reporter construct pCMVluc+. Four ducks were treated with AdlacZ-Lig/pL containing 1 × 10 9 pfu adenoviral particles and 20 g pCMVluc+ (corresponding to 3 × 10 12 plasmid molecules) as carrier DNA. Two days later the ducks were killed and luciferase expression was analyzed. No luciferase activity could be detected in any animal (data not illustrated).
We then analyzed the specific tissue distribution of the gene transfer by adenoviral, receptor-mediated delivery to spleen, kidney, heart, lung and pancreas by X-gal staining of tissue sections. In ducks treated with AdlacZLig/pL no ␤-gal activity was present in kidney, heart, lung and pancreas, low-level ␤-gal activity was present in spleen. However, the low ␤-gal activity present in spleen of ducks treated with AdlacZ-Lig/pL could be detected at the same level in ducks treated with AdlacZ alone (data not illustrated).
Discussion
Efficient delivery systems for the targeted in vivo gene transfer and expression are of central importance to gene therapy research. Here we achieved adenoviral infection via a specific hepatocyte receptor independent from the natural viral receptor thus demonstrating the feasibility of modifying the tropism of adenoviruses in vivo. Main factors which may contribute to this successful gene delivery are the physical integrity of AdlacZ-Lig/pL, the absence of relevant restrictions imposed by the microcirculation of the liver and the power of virus-evolved mechanisms for intracellular trafficking and gene expression. Our previous work 36 could define optimal conditions for the preparation and the composition of the delivery complex. Future work will address the issue of how many ligands have to be attached to the virion to mediate efficient tissue targeting. Similar biophysical investigations by Wu et al 34 lead to the conclusion that approximately 24 molecules of conjugate were bound to each viral particle.
From our data it cannot be excluded that additional factors contribute to the efficiency of gene delivery. It is conceivable that aggregation of virus particles preceding specific binding and internalization enhances settling on to the cells and thus augments gene transduction.
Streptavidin was included originally in the protein conjugate to form specific complexes with biotinylated adenovirus particles through the biotin-streptavidin bridge as described previously. 31 Different from these data 31 in our system, the adenovirus particles did not have to be biotinylated before complex formation with the conjugate. The complexes prepared with biotinylated or nonbiotinylated virus particles showed identical DNA delivery efficiencies. In parallel with previous results in tissue culture, 36 delivery complexes containing a protein conjugate with streptavidin gave about 50% greater DNA delivery efficiency than those without streptavidin in vivo. The precise mechanism underlying this phenomenon remains to be elucidated.
Interestingly, gene transduction was much more efficient when the transgene was delivered as an integral part of the adenoviral genome rather than in the form of an additional separate expression vector. This may be due to degradation of DNA during endocytosis, unfavorable intracellular localization, inefficient nuclear translo- cation of the DNA plasmid 38 or the strength of the viral transgenes occupying the cellular resources.
Since the CHL is expressed in the liver only, AdlacZLig/pL complexes should only target liver tissue. Indeed, our data demonstrate a striking tissue specificity of the complex. The low-level ␤-gal activity present in spleen of ducks treated with AdlacZ-Lig/pL could be detected at the same level in ducks treated with AdlacZ alone. Hence, unspecific uptake of AdlacZ by splenocytes might account for this observation.
A further characteristic of our system is the use of a distant adenovirus species. Our in vitro and in vivo data demonstrate the drastically reduced infectivity of such a distant adenovirus species, which can be bypassed by targeting a species-specific receptor. The use of a distant adenovirus species may result in reduced toxicity and fewer safety hazards. This notion is supported by the observation that no significant cytopathic effects could be seen when incubating the chicken hepatoma cells with human adenovirus dl312. 36 By contrast, a full cytopathic effect was previously observed when incubating the chicken hepatoma cells with the replication competent, recombinant avian adenovirus type 5 (CELO) at much lower virus concentrations. 36 Cotten et al, 37 using CELO virus and human cell lines, also did not observe a cytopathic effect, clearly demonstrating the species specificity of the cytopathology of adenoviruses.
In conclusion, this study demonstrates for the first time the efficient CHL-mediated retargeting of a recombinant adenoviral vector in vivo in an animal model. The results Gene Therapy may be extended to other virus-associated delivery strategies and other target organs. In particular, viruses that are not hepatotropic by nature may thus be usable for hepatic gene transfer.
Materials and methods

Animals
One-day-old ducklings (Anas domesticus) were purchased from a duck farm (Wichmann, Ermke, Germany). For in vivo gene transfer experiments 5-day-old ducklings were injected into the foot vein and killed 48 h later.
Cells and media
The chicken hepatoma cell line LMH, 293 and 911 cells were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 8% fetal calf serum. The human hepatoma cell line HepG2 was maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Primary duck hepatocytes were isolated from 10-day-old Pekin ducks as described 39 with only minor modifications. 40 The hepatocytes were seeded at a density of 2 × 10 5 cells/cm 2 on Primaria tissue culture dishes using Williams' medium E supplemented with 20 mm HEPES (pH 7.4), 5 mm glutamine, 0.066 m insulin, 10 mm dexamethasone, 100 g/ml penicillin, 100 g/ml streptomycin and 1.5% dimethyl sulfoxide. The cultures were maintained at 37°C and 5% CO 2 in a humidified incubator.
Preparation and purification of protein conjugates
The standard coupling mixture contained 0.3 mg of Nacetylglucosamine derivative of BSA (albumin-p-aminophenyl-N-acetyl-b-d-glucosamide; catalog no. A1043; Sigma, St Louis, MO, USA), 0.3 mg of streptavidin (Pierce, Rockford, IL, USA), 1.2 mg of poly-l-lysine hydrochloride (Sigma, molecular weight of 36 700), 12.5 mmol/l 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide (Pierce), and 12.5 mmol/l of N-hydroxy-sulfosuccinimide (Pierce). The mixture was incubated at room temperature for 14-18 h. Then 1 vol of 1 mol/l of l-lysine was added, and the incubation was continued for another 4 h. To separate free ligand after the complexation process the conjugates were purified by high-performance liquid chromatography using a strong cation exchange column (Protein-Pak SP-8HR, 5 × 50 mm; Waters, Milford, MA, USA). After equilibration of the column with buffer A (0.02 mol/l of sodium phosphate, pH 7.0), the coupling mixture was applied directly to the column. The column was washed with buffer A. The conjugate was eluted with a linear NaCl gradient (0-3 mol/l) in buffer A. Fractions eluted between 1.45 mol/l and 2.1 mol/l of NaCl containing the conjugate were pooled, diluted 1:1 with water, concentrated four to six times using Ultrafree-CL filters UFC4LT-K25 (Waters Chromatography Division, Millipore), and stored at −20°C until use.
Preparation of adenovirus
The propagation and purification of the replication-defective human adenovirus dl312 and the replication-defective human recombinant adenoviruses AdlacZ and AdGFP followed the procedure previously described. 36 For large-scale preparation, the 293 cells were cultured to near confluency in four 750-ml Falcon flasks in Iscove's modified Dulbecco's medium (IMDM), supplemented with 10% fetal calf serum (FCS). After aspiration of the culture medium, 3.5 ml of an adenovirus suspension, containing about 3.5 × 10 5 virus particles diluted in phosphate-buffered saline (PBS), containing calcium and magnesium ions, was added to each flask. The cells were incubated for 1 h at 37°C at 5% CO 2 atmosphere in a humidified incubator. The adenovirus suspension was then replaced with 30 ml of IMDM containing 2% FCS, and the incubation was continued until the full cytopathic effect was observed (about 60 h). The adherent cells were detached using a plastic policeman. The cell suspension was centrifuged for 5 min at 175 g. The pellets from all four culture flasks were resuspended in a total of 5.0 ml of PBS. The cell suspension was transferred to an SS-34 Sorvall tube, containing 1 g of washed, sterile glass beads (diameter 425-600 m; Sigma). To lyse the cells, 0.6 ml of 5% sodium deoxycholate (Fluka, Buchs, Switzerland) was added. After vigorous mixing, the suspension was incubated on ice for 30 min. The thick cell lysate was vortexed for about 30-40 s to shear the chromosomal DNA, and the suspension was centrifuged twice (5000 g for 5 min at 4°C) to remove cell debris and glass beads. The virus was then purified by two rounds of centrifugation in a CsCl gradient, using two 5-ml quick-seal tubes each time. CsCl was removed by Sephadex G-25 chromatography. The purified virus was concentrated using Ultrafree-CL filters UFC4 TMK25 (Millipore) and stored at −80°C. The virus particle concentration was determined as described previously. 41 
Formation of delivery complexes
The preparation of the delivery complex followed the standard protocol: 36 2 l of conjugate (0.35-0.75 g of protein) and 5 l of adenovirus (total 1 × 10 7 virus particles) were added to 193 l of IMDM. After 30 min at room temperature, 50 l of carrier DNA solution containing 200 ng DNA was added and the incubation was continued for an additional 30 min. After the addition of 28 l of 10% FCS and 222 l of IMDM supplemented with 10% FCS the delivery complex mixture was ready for use.
Reporter assays X-gal was used for the in situ detection of ␤-gal activity as described previously. 36 The Galactolight Chemiluminescent Reporter Assay (Tropix, Bedford, MA, USA) was used to quantify the activity of ␤-gal according to the manufacturer's recommendations. Relative light units (RLU) were determined using a luminometer (EG&G Berthold, Jena, Germany). Luciferase assays were performed following a standard protocol. 42 A Zeiss Axiovert photomicroscope equipped with an epifluorescence attachment was used to view cells expressing GFP. Examination by flow cytometry followed standard protocols. 43 Other methods AdlacZ is the replication-defective recombinant strain dl312 of the human adenovirus serotype 5 containing the lacZ gene under the control of cytomegalovirus promoter and enhancer. AdGFP is the replication-defective recombinant strain of the human adenovirus serotype 5 containing the GFP gene under the control of cytomegalovirus promoter and enhancer. Plasmid pCMVluc+ 42 allows expression of the firefly luciferase gene under the control of the cytomegalovirus immediate-early promoter. Plasmids were purified by two rounds of CsClgradient banding. 44 
